TrialCurveSTARGATE: reconstructed Kaplan–Meier curves
Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE). Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Cancer Med. 2022 Dec 14;12(7):7784–94. doi: 10.1002/cam4.5536 |
|---|---|
| DOI | 10.1002/cam4.5536 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival (blinded central radiologic review)
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: S+XP 5.5 months; XP 5.3 months. Survival at 6 months: S+XP 43%; XP 36%. Hazard ratio S+XP vs XP 0.89 (95% CI 0.64–1.22).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| S+XP | 97 | 76 | 5.5 |
| XP | 98 | 78 | 5.3 |
- S+XP vs XP: reconstructed HR 0.89 (95% CI 0.64–1.22)
Landmark survival (reconstructed)
| Time | S+XP | XP |
|---|---|---|
| 6 mo | 42.9% | 36.2% |
| 12 mo | 9.7% | 3.3% |
| 18 mo | 4.2% | — |
Checks against the published figure
- S+XP median: printed 5.6, reconstructed 5.53 pass
- XP median: printed 5.3, reconstructed 5.27 pass
Overall survival
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: XP 10.3 months; S+XP 11.7 months. Survival at 12 months: XP 43%; S+XP 49%. Hazard ratio XP vs S+XP 1.09 (95% CI 0.77–1.54).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| XP | 98 | 63 | 10.3 |
| S+XP | 97 | 66 | 11.7 |
- XP vs S+XP: reconstructed HR 1.09 (95% CI 0.77–1.54)
Landmark survival (reconstructed)
| Time | XP | S+XP |
|---|---|---|
| 6 mo | 80.0% | 80.4% |
| 12 mo | 43.3% | 48.7% |
| 18 mo | 21.7% | 27.1% |
| 24 mo | 15.4% | 16.5% |
Checks against the published figure
- S+XP median: printed 11.7, reconstructed 11.7 pass
- XP median: printed 10.8, reconstructed 10.3 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/stargate-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/stargate-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Cancer Med. 2022 Dec 14;12(7):7784–94. doi: 10.1002/cam4.5536 doi:10.1002/cam4.5536. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/stargate
Report a problem with these data
Related trials
- JACOB (Chinese subgroup): Overall survival; Progression-free survival (investigator-assessed)
- ATTRACTION-2 (2-year update): Overall survival; Progression-free survival
- Gastrectomy and second-line chemotherapy in advanced gastric cancer: Overall survival; Overall survival (IPTW-adjusted); Progression-free survival; Progression
- KEYNOTE-590 (Japanese subgroup, extended follow-up): Overall survival; Progression-free survival
- OE05: Overall survival
- Preoperative chemoradiotherapy vs chemotherapy in gastric/GEJ cancer: Disease-free survival; Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials